Medications for breast, prostate, colorectal and urothelial cancer have won positive recommendations for PBS listing from the Pharmaceutical Benefits Advisory Committee (PBAC). At its March 2021 meeting the PBAC made the following positive recommendations: Abemaciclib for breast cancer. The PBAC recommended the listing of abemaciclib (Verzenio)in combination with fulvestrant, for the treatment of non-premenopausal patients ...
Five oncology therapies win approval for PBS listing
By Michael Woodhead
28 Apr 2021